Dent Neurological Institute

Amherst, New York 14266

3 studies enrolling now · 24 studies all time

What they study most

Alzheimer's Disease, Chronic Migraine, Cognition Disorders, Episodic Cluster Headache, Essential Tremor, Headache, Headache Disorders, Headache, Migraine, Huntington Disease, Huntingtons Disease, Lewy Body Dementia, Migraine

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease — Recruiting now
• A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression — Recruiting now
• Responding With Evidence and Access for Childhood Headaches — Recruiting now
• Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss — Completed
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis — Running, not enrolling
• GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease — Running, not enrolling
• A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET) — Completed
• A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease — Completed
• An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies — Completed
• A Study of Lasmiditan (LY573144) Over Four Migraine Attacks — Completed
• Evaluation of Galcanezumab in the Prevention of Chronic Migraine — Completed
• A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) — Completed
• A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia — Stopped early
• Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia — Completed
• A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). — Stopped early
• Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study — Completed
• Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo — Stopped early
• A Study Of Galcanezumab In Participants With Episodic Cluster Headache — Completed
• The Childhood and Adolescent Migraine Prevention Study — Stopped early
• DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease — Completed
• ADNI: Alzheimer's Disease Neuroimaging Initiative — Completed
• Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 — Completed